0001209191-19-034861.txt : 20190605 0001209191-19-034861.hdr.sgml : 20190605 20190605174952 ACCESSION NUMBER: 0001209191-19-034861 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190603 FILED AS OF DATE: 20190605 DATE AS OF CHANGE: 20190605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MOORE ALISON CENTRAL INDEX KEY: 0001754937 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38693 FILM NUMBER: 19880877 MAIL ADDRESS: STREET 1: C/O ALLOGENE THERAPEUTICS, INC. STREET 2: 210 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allogene Therapeutics, Inc. CENTRAL INDEX KEY: 0001737287 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 823562771 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 210 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 457-2700 MAIL ADDRESS: STREET 1: 210 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-03 0 0001737287 Allogene Therapeutics, Inc. ALLO 0001754937 MOORE ALISON 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Technical Officer Common Stock 2019-06-03 4 M 0 48828 2.27 A 86385 D Common Stock 2019-06-03 4 S 0 47205 26.7441 D 39180 D Common Stock 2019-06-03 4 S 0 1623 27.3069 D 37557 D Option to Purchase Common Stock (Right to Buy) 2.27 2019-06-03 4 M 0 48828 0.00 D 2028-06-25 Common Stock 48828 843672 D Includes 507 shares of the Issuer's common stock acquired by the reporting person on March 15, 2019 pursuant to an employee stock purchase program. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.30 to $27.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.30 to $27.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter. /s/ Veer Bhavnagri, Attorney-in-Fact 2019-06-05